A patient-friendly
approach to
Improved Cancer
Care

Our focus is the development of
patient-friendly and preventative
therapies that make a major, positive
difference to cancer patients’ well-being
and quality of life, with substantial payer
savings potential.

VasoDynamics

Who we are

VasoDynamics is a Stevenage and London based, clinical-stage pharmaceutical development company. We are solely focused on developing patient-friendly, cost-effective medicines to prevent the severe side-effects induced by anticancer therapies.

Our philosophy is to generate affordable medicines that enable cancer patients to tolerate widely used anticancer therapies, with the dual purpose of enhancing the efficacy of anti-cancer therapy and improving patients’ quality of life with cancer, without painful, traumatic or debilitating side-effects.

VasoDynamics homepage two

Our Programmes

Our programmes are designed to prevent the common complications of cancer therapy, including mouth ulceration, dermatitis, and (permanent) hair-loss.

VasoDynamics

Who we are

VasoDynamics is a Stevenage and London based, clinical-stage pharmaceutical development company. We are solely focused on developing patient-friendly, cost-effective medicines to prevent the severe side-effects induced by anticancer therapies.

Our philosophy is to generate affordable medicines that enable cancer patients to tolerate widely used anticancer therapies, with the dual purpose of enhancing the efficacy of anti-cancer therapy and improving patients’ quality of life with cancer, without painful, traumatic or debilitating side-effects.

VasoDynamics homepage two

Our Programmes

Our programmes are designed to prevent the common complications of cancer therapy, including mouth ulceration, dermatitis, and (permanent) hair-loss.

The VasoDynamics Pipeline

The company’s technology is currently differentiated in three formulation platforms with several product pipelines for the protection of
skin, mucosa and hair for various types of cancer patients.

VasoDynamics medical icons

NG11

Prevention of radiation-induced
oral mucositis (RIOM)

VasoDynamics medical icons

NG12

Prevention of radiation-induced
dermatitis

VasoDynamics medical icons

NG13

Prevention of chemotherapy-induced
alopecia (hair loss)

The VasoDynamics Pipeline

The company’s technology is currently differentiated in three formulation platforms with several product pipelines for the protection of
skin, mucosa and hair for various types of cancer patients.

VasoDynamics medical icons

NG11

Prevention of radiation-induced
oral mucositis (RIOM)

VasoDynamics medical icons

NG12

Prevention of radiation-induced
dermatitis

VasoDynamics medical icons

NG13

Prevention of chemotherapy-induced
alopecia (hair loss)

Our Latest News:

Clinical & Scientific Advisory Board
VasoDynamics strengthens the Board with key appointments

Building a strong Board of industry experts to enable progress to market acces

Our Latest News:

NG11-2 Phase Ib clinical trial
NG11-2 Phase-Ib Study Closes Enrolment – Results Expected Autumn 2024

A Phase-1b Dose Escalation Study to Assess the Effect of NG11-2 on Radiation Induced Oral Mucositis (RIOM) in Patients with Head & Neck Cancer.